99865-15-3

Upstream product

• 6622-76-0 methyl (E)-2-methyl-2-butenoate 
• 41103-90-6 (1-phenyl-ethyl)-malonic acid 
• 109-89-7 diethylamine 
• 847654-05-1 (+/-)-methyl 2-methylene-3-phenylbutanoate 
• 585-71-7 (1-bromoethyl)benzne 
• 81699-67-4 ethyl 2-methylene-3-phenylbutanoate 

Downstream Products

• 150881-36-0 (S)-2-(2-Acetylsulfanylmethyl-3-phenyl-butyrylamino)-propionic acid benzyl ester 
• 155895-89-9 (S)-2-((2R,3R)-2-Mercaptomethyl-3-phenyl-butyrylamino)-propionic acid 
• 155895-89-9 (S)-2-((2R,3S)-2-Mercaptomethyl-3-phenyl-butyrylamino)-propionic acid 
• 155895-89-9 RB 105 
• 155895-89-9 (S)-2-((2S,3S)-2-Mercaptomethyl-3-phenyl-butyrylamino)-propionic acid 
• 155895-89-9 (S)-2-(2-Mercaptomethyl-3-phenyl-butyrylamino)-propionic acid 
• 150881-70-2 (2R,3R)-2-<(acetylthio)methyl>-3-phenylbutanoic acid 
• 150881-68-8 (2R,3S)-2-<(acetylthio)methyl>-3-phenylbutanoic acid 
• 150881-69-9 (2S,3R)-2-<(acetylthio)methyl>-3-phenylbutanoic acid 
• 155779-75-2 (2S,3S)-2-<(acetylthio)methyl>-3-phenylbutanoic acid 

Relevant academic research and scientific papers

Mapping the mechanism of nickel-ferrophite catalysed methylation of baylis-hillman-derived SN2′ electrophiles

Enantioselective Ni-catalysed methylation of Baylis-Hillman-derived allylic electrophiles in the presence of ferrophite ligands has been investigated computationally and experimentally. The sense and degree of enantioselectivity attained is independent of both the leaving group and the isomeric structure of the initial allylic halide. DFT studies support the selective formation of a limited number of energetically favoured anti and syn π-allyl intermediates. The observed regio- and enantioselectivity can be rationalised based on the energetics of these structures.

Toward an optimal joint recognition of the s1′ subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP)

The formation of vasoconstrictors (e.g., angiotensin II and endothelin) and the inactivation of vasodilators (e.g., bradykinin and atrial natriuretic) by membrane-bound zinc metallopeptidases are key mechanisms in the control of blood pressure and fluid h

Process for the synthesis of α-substituted acrylic acids and their application

Process for the synthesis of a-substituted acrylic acids and their application. Process for the synthesis of a-substituted acrylic acids of general formula (I) and their application to the synthesis of N- (mercaptoacyl) aminoacid derivatives of formula (II). STR1

N-[MERCAPTOACYL(AMINO ACID OR PEPTIDE)] COMPOUNDS AND S-LIPOPHILIC ALIPHATIC CARBONYL DERIVATIVES THEREOF AS ANTIHYPERTENSIVES

N-[Mercaptoacyl(amino acid or peptide)] compounds and S-lipophilic aliphatic carbonyl derivatives thereof, and pharmaceutical compositions comprising such compounds, as well as the use of these compounds as antihypertensives by the inhibition of neutral endopeptidase and/or peptidyldipeptidase A are disclosed. Methods for preparing the such compounds and derivatives are disclosed also.

New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: Rational design, bioavailability, and pharmacological responses in experimental hypertension

In the treatment of cardiovascular diseases, it could be of therapeutic interest to associate the hypotensive effects resulting from the inhibition of angiotensin II formation, ensured by endothelial angiotensin-converting enzyme (ACE), with the diuretic

N-(mercaptoacyl)amino acids, methods of their preparation and therapeutic use, and pharmaceutical compositions containing them

The present invention is directed to a compound of the formula (I) wherein, R represents a hydrogen atom or an acyl, aroyl or cycloalkylcarbonyl radical or a residue of formula R1 represents an alkyl radical;, R2 represents an aryl o